Research Topics
Species | Jessica M Faupel-BadgerSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancerJessica M Faupel-Badger
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 4254, USA
Cancer Epidemiol Biomarkers Prev 15:1153-8. 2006....
Evaluating postgraduate public health and biomedical training program outcomes: : lost opportunities and renewed interestJessica Faupel-Badger
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Cancer Educ 28:18-26. 2013..Suggestions for increasing interest in conducting and reporting evaluation studies of these structured postgraduate training programs are provided...
Cluster analysis of placental inflammatory proteins can distinguish preeclampsia from preterm labor and premature membrane rupture in singleton deliveries less than 28 weeks of gestationJessica M Faupel-Badger
Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892 7105, USA
Am J Reprod Immunol 66:488-94. 2011..The risks of complications are different between iatrogenic (e.g. PE) and spontaneous (e.g. PL and membrane rupture) causes of preterm delivery, suggesting different underlying biology contributes to these placental conditions...- Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnanciesJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Bethesda, MD 20892 7105, USA
Cancer Causes Control 23:779-84. 2012..This study sought to compare an extensive profile of biological markers in both maternal and umbilical cord samples in preeclamptic and uncomplicated pregnancies of a predominantly African-American population... - Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and genderJessica M Faupel-Badger
Cancer Prevention Fellowship Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Ann Epidemiol 19:841-9. 2009..S. population-based study where these associations could also be stratified by race/ethnicity and gender... - Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogensJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Bethesda, MD 20892 7105, USA
Cancer Epidemiol Biomarkers Prev 19:292-300. 2010..2% and < or =17.8%). Comparison with the LC-MS/MS method suggests that the widely used RIA and ELISA estrogen metabolite measures may be problematic, especially at low estrogen metabolite levels characteristic of postmenopausal women... - Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish menJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Division of Cancer Prevention and Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, 37 Convent Drive, Building 37, Room 1106, Bethesda, MD 20892-4254, USA
Cancer Epidemiol Biomarkers Prev 16:2784-6. 2007 - Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from PolandJ M Faupel-Badger
Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, 6120 Executive Blvd EPS, Suite 150E, MSC 7105, Bethesda, MD 20892, USA
Br J Cancer 103:1097-102. 2010.... - Association of IL-10 polymorphisms with prostate cancer risk and grade of diseaseJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Division of Cancer Prevention and Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 4254, USA
Cancer Causes Control 19:119-24. 2008..56, 95% CI 1.26-5.20 for -819). These data demonstrate genotypes correlated with low IL-10 production are associated with increased risk of prostate cancer and with high-grade disease in this population... - Plasma volume expansion in pregnancy: implications for biomarkers in population studiesJessica M Faupel-Badger
Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, MSC 4254, 37 Convent Drive, Bethesda, MD 20892, USA
Cancer Epidemiol Biomarkers Prev 16:1720-3. 2007..We present PVE as a topic for consideration in population-based studies, examples of the types of studies where PVE may be relevant, and our own analysis of one such study in the text below... - Maternal angiogenic profile in pregnancies that remain normotensiveJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Rockville, MD USA
Eur J Obstet Gynecol Reprod Biol 158:189-93. 2011..We sought to determine if maternal characteristics are associated with angiogenic profile in the first and second trimester of normotensive pregnancies... - Expanding cancer prevention education to national and international audiences: the National Cancer Institute's Principles and Practice of Cancer Prevention and Control annual summer courseJessica M Faupel-Badger
National Cancer Institute, Cancer Prevention Fellowship Program, Bethesda, MD 20892 7105, USA
J Cancer Educ 26:619-25. 2011.... - Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axisJessica M Faupel-Badger
Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, 6120 Executive Blvd EPS, Bethesda, MD 20892 7105, USA
Cancer Causes Control 22:1587-95. 2011.... - Pregnancy weight gain is not associated with maternal or mixed umbilical cord estrogen and androgen concentrationsJessica M Faupel-Badger
Division of Cancer Prevention and Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7105, USA
Cancer Causes Control 20:263-7. 2009..Our results are not consistent with an effect of pregnancy weight gain being mediated by this pathway as reflected by hormone concentrations at the end of pregnancy... - Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancerJennifer Eng-Wong
Division of Cancer Prevention and Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1906, USA
Cancer Epidemiol Biomarkers Prev 12:1468-73. 2003..Increases in IGFBP-3 may potentially decrease the activity of circulating IGF-I. The effect of modulating the IGF pathway and leptin on breast cancer risk needs additional evaluation... - A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancerJo Anne Zujewski
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Breast Cancer Res Treat 81:41-51. 2003..Administration of dose dense AC followed by infusional paclitaxel in 14-day cycles is feasible and this regimen is active in breast cancer... - Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in PolandSarah J Nyante
Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852, USA
Breast Cancer Res 13:R42. 2011..Thus, we examined the relationship between single nucleotide polymorphisms (SNPs) in PRL and PRLR, serum prolactin levels and breast cancer risk in a population-based case-control study... - Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancerJennifer Eng-Wong
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Cancer Epidemiol Biomarkers Prev 17:1696-701. 2008..We evaluated the effect of raloxifene on mammographic density and MRIV in premenopausal women at increased risk for breast cancer... - Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancerGretchen L Gierach
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Office of Preventive Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Breast Cancer Res Treat 123:245-55. 2010..Taking these factors into account did not significantly alter the results of the age/body mass index-adjusted analysis. Our results do not provide support for an independent effect of BRCA1/2 mutation status on mammographic density... - A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz
Medical Oncology Clinical Research Unit, National Cancer Institute NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA
Clin Cancer Res 11:1247-52. 2005..We studied the safety and toxicity of tipifarnib in combination with tamoxifen in metastatic breast cancer. The pharmacokinetics and pharmacodynamics of tipifarnib were also assessed... - Gynecologic and hormonal effects of raloxifene in premenopausal womenAhalya Premkumar
Department of Diagnostic Radiology, Warren G Magnuson Clinical Center, Bethesda, Maryland, USA
Fertil Steril 88:1637-44. 2007..To assess the effects of raloxifene on the ovaries, uterus, and serum hormone levels in premenopausal women... - Association of serum sex steroid hormone hemodilution and body mass index among healthy postmenopausal womenHannah P Yang
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Ann Epidemiol 21:466-71. 2011..Assessing the relationship of hormone concentration to total mass varies by body mass index (BMI) is etiologically important because obesity is related to hormone metabolism and cancer risk... - Raloxifene and its role in breast cancer preventionJennifer Eng-Wong
National Cancer Institute, Medical Oncology Clinical Research Unit, Bldg 10, Rm 12N226, Bethesda, MD 20892, USA
Expert Rev Anticancer Ther 4:523-32. 2004..The utility of raloxifene will depend on the outcome of trials that are now underway, as well as acceptance by high-risk women and their healthcare practitioners... - Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshopJessica M Faupel-Badger
Cancer Prevention Fellowship Program and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
J Natl Cancer Inst 105:166-74. 2013..This report summarizes conclusions of the workshop, proposes avenues for future research on the PLC and its relationship with breast cancer risk, and identifies opportunities to translate this knowledge to improve breast cancer outcomes... - Sentinel lymph node biopsy in the management of ductal carcinoma in situJoAnne Zujewski
National Cancer Institute, Bethesda, MD 20892, USA
Clin Breast Cancer 6:216-22. 2005..Sentinel lymph node biopsy in DCIS is associated with known risks, and health care benefits, if any, have not been demonstrated. Sentinel lymph node biopsy is not recommended in patients with DCIS... - Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancerJennifer Eng-Wong
Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Cancer 112:723-9. 2008..Close research partnerships that promote large-scale translational research are essential to the continuation of rapid achievements in this field... - Preparation of human serum for prolactin measurement by multiple reaction monitoring mass spectrometryTimothy J Waybright
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Methods Mol Biol 1002:195-203. 2013.... - Outcome evaluation of the national cancer institute career development awards programJulie L Mason
Center for Cancer Training, Office of the Director, National Cancer Institute, 6116 Executive Boulevard, Suite 700, MSC 8346, Rockville, MD, 20852 8346, USA
J Cancer Educ 28:9-17. 2013..The NCI K program had a positive impact, not only on participants' biomedical research careers but also on achieving outcomes significant to the scientific enterprise... - A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz
Medical Oncology Clinical Research Unit, Cancer Therapeutics Branch, Laboratory of Pathology, Biostatistics and Data Management, and Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:6764-9. 2004..CONCLUSIONS: Docetaxel/capecitabine is a highly active regimen in the neoadjuvant setting. Neoadjuvant therapy with 75 mg/m(2) docetaxel and 1600 mg/m(2)/day days 2-15 is recommended... - Effect of raloxifene on salivary sex steroid concentrations in premenopausal womenRobert T Chatterton
Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
J Endocrinol 191:599-604. 2006..The results reflect increases in serum oestradiol reported earlier...